The significant increase in Novo Nordisk's market value and sales figures, along with the expected sales growth, suggest a positive short-term impact on the stock price. The company's proactive measures to expand production capacity in response to high demand for its drugs further reinforce this outlook. However, the presence of counterfeit drugs and competition from Eli Lilly could present challenges, but the market appears to be focusing on the strong financial performance and growth potential.